Abstract 123P
Background
Our phase Ib NIBIT Foundation M4 study firstly reported that administration of the hypomethylating agent (DHA) guadecitabine (guade), a prodrug of decitabine (D), followed by I in metastatic melanoma (MM) patients (pts) is safe and has promising clinical and tumor immune-modulating activity (Di Giacomo, CCR 2019). To further explore the activity of DHA combined with immune-checkpoints blockade, the NIBIT-ML1 trial is investigating the efficacy of guade plus I and N in PD-1/PD-L1 resistant MM or NSCLC pts. The run-in phase of the study is reported.
Methods
The NIBIT-ML1 is a randomized, phase II study (Simon two stages optimal design), in unresectable Stage III/IV MM (Cohort A) or NSCLC (Cohort B) pts progressing to anti-PD-1/PD-L1. A trial amendment substituted guade with ASTX727, an oral formulation of D with cedazuridine. Following the safety run-in of 6 subjects per Cohort, eligible pts are randomized to ASTX727 plus I and N or I and N. Primary objective is immune(i)-ORR; secondary are safety, DCR, PFS, median OS, survival rate at 1- and 2-year. For PK analyses D was measured in plasma as active drug after oral ASTX727 or as active metabolite after s.c. guade. Extensive cellular and molecular immunocorrelates are also explored.
Results
Cohort A. Six pts [4 male; median age 71 years, ECOG 0-1] with Stage III/IVMM, received guade (2 pts) or ASTX727 (4 pts) plus I and N. No DLT or overlapping toxicities occurred. Any grade (G) treatment-related AEs occurred in 6 (100%) pts, 50% were G3/4. Three PR, 2 SD, and 1 PD were observed. Cohort B. Six pts [2 male; median age 70 ECOG 0-1] with Stage III/IV NSCLC received guade (2 pts) or ASTX727 (4 pts) plus I and N. Two DLTs occurred. Any G treatment-related AEs occurred in 5 (83.3%) pts, 67% were G3/4. One CR, 2 SD and 3 PD were observed. PK analyses showed that D systemic exposures (mean AUC) dosed as 20mg ASTX727 and dosed at 80mg guade (∼45 mg/m2) were similar. Mean (% CV) D AUC 0-24 for combined Cohorts A and B after ASTX727 was 114 (90%) ng*hr/mL (n=8), and after guade was 110 (21%) ng*hr/mL (n=4).
Conclusions
Treatment with ASTX727 plus I and N is feasible in PD-1/PD-L1 refractory MM and NSCLC pts. The Stage 1 of the NIBIT-ML1 study is recruiting.
Clinical trial identification
NCT04250246, EudraCT 2019-002986-36.
Legal entity responsible for the study
NIBIT Foundation Onlus.
Funding
NIBITFoundation Onlus with unresctricted grant from Astex Pharmaceuticals and Bristol Myers Squibb.
Disclosure
A.M. Di Giacomo: Financial Interests, Personal, Advisory Board: Incyte, Pierre Fabre, GSK, Bristol Myers Squibb, Merck Sharp Dohme, Sanofi; Financial Interests, Personal, Other, Educational activities: Bristol Myers Squibb, Merck Sharp Dohme, Pierre Fabre, Sanofi. L. Calabro: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Merck Sharp and Dohme, Roche; Financial Interests, Personal, Other, Educational activities: Bristol Myers Squibb, AstraZeneca, Sanofi. M. Valente: Financial Interests, Personal, Advisory Board: Novartis. H.N. Keer, A. Oganesian, D. Chan: Financial Interests, Personal, Full or part-time Employment: Astex Pharmaceuticals. M. Ceccarelli: Financial Interests, Personal, Advisory Board: Moderna Therapeutics; Financial Interests, Personal, Funding: Immunomica srl. M. Maio: Financial Interests, Personal, Advisory Board: Roche, Bristol Myers Squibb, Merck Sharp Dohme, Incyte, AstraZeneca, Amgen, Pierre Fabre, Eli Lilly, GSK, Sciclone, Sanofi, Alfasigma, Merck Serono; Financial Interests, Personal, Ownership Interest: Theravance, Epigen Therapeutics, Srl. All other authors have declared no conflicts of interest.
Resources from the same session
26P - Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to Cabozantinib (CABO) plus Durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the Phase 2 ARCADIA trial)
Presenter: Veronica Huber
Session: Poster Display
27P - Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with Cabozantinib (CABO) plus Durvalumab (DURVA): preliminary analysis from the Phase 2 ARCADIA trial.
Presenter: Francesco Sgambelluri
Session: Poster Display
28P - 3-year follow-up analysis of disease-free survival in CheckMate 274 by PD-L1 expression using tumor cell and combined positive scoring algorithms
Presenter: Frank Stenner-Liewen
Session: Poster Display
30P - CD4+ T cells within the tumor microenvironment are an independent predictor of recurrence, but do not improve the performance of a predictive model in oral squamous cell carcinoma
Presenter: Sangeeta Bisheshar
Session: Poster Display
31P - Characterization of pre-exhausted / exhausted state of CD8+ T cells in HRAS mutant head and neck carcinomas (HNSCCs). Implications for response to immune checkpoint blockade (ICB).
Presenter: Ioannis Kotsantis
Session: Poster Display
32P - Tumor-agnostic plasma assay for circulating tumor DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor
Presenter: Natasha Honoré
Session: Poster Display
34P - Heterogeneous response to Immune Checkpoint Inhibitors in metastatic melanoma patients - assessment of lesion-level response with 18F-FDG PET/CT
Presenter: Katja Strasek
Session: Poster Display